Highest-materiality recent filing
DENTSPLY SIRONA amends credit facility and notes to keep leverage covenants in compliance
Third Amendment to Credit Agreement (Sept 30, 2026), with JPMorgan Chase as administrative agent, raises max Total and Senior Leverage Ratios for quarters ending Sept 30 and Dec 31, 2026.
Dentsply Sirona Q2 2026: net sales $898M (-4.1% YoY), adj EPS $0.52 flat
Net sales $898M, down 4.1% YoY; GAAP diluted EPS $0.18 vs. ($0.22) loss in Q2 2025.
Dentsply Sirona Q2 net sales $898M (-4.1% YoY); adjusted EPS $0.52 flat; reaffirms FY outlook
GAAP diluted EPS $0.18 vs loss of $0.22 in Q2 2025; adjusted EPS $0.52 flat YoY.
Dentsply Sirona appoints John Fortson as EVP & CFO; base salary $780K
John Fortson named EVP & CFO effective July 20, 2026; previously CFO at Kymera International and CEO at Ingevity.
Dentsply Sirona Q1 adj EPS $0.27, down 39% YoY; net sales flat at $880M
GAAP net loss per share ($0.05); adjusted EPS $0.27 vs $0.44 in Q1 2025.
Q4 net sales $961M (+6.2% reported, +2.5% constant currency); reported diluted EPS ($0.74) from $144M impairments.
Dentsply Sirona renews U.S. dental technology distribution agreement with Patterson Dental
Renewed non-exclusive agreement covers Dentsply Sirona's full portfolio including CEREC, Primescan, Axeos, and Orthophos systems.
Dentsply Sirona amends debt covenants; new leverage ratios step down to 3.50x, restricts dividends
New Total Leverage Ratio covenant: cannot exceed 4.25x (Q4 2025–Q2 2026) stepping down to 3.50x (Q3 2027+).
CFO Matthew Garth to depart Nov 5; CEO Scavilla takes interim CFO role
Matthew E. Garth will leave as EVP and CFO effective November 5, 2025.
Dentsply Sirona Q3 net sales down 5% to $904M; GAAP loss $2.14/share; cuts FY25 outlook
Net sales $904M, down 5.0% as-reported, 8.0% constant currency; GAAP net loss per share ($2.14).
SEC concludes investigation of Dentsply Sirona without enforcement action
SEC's Division of Enforcement closed its investigation initiated May 2022.
EVP, General Counsel & Secretary Richard Rosenzweig departs; becomes Special Legal Advisor
Richard C. Rosenzweig ceases role as EVP, Corporate Development, General Counsel and Secretary effective Oct 3, 2025 by mutual agreement.
Dentsply Sirona Retains Wellspect Healthcare After Strategic Review, Ends Sale Process
Strategic review of Wellspect begun Feb 2025 completed Sep 8, 2025; company decided to retain the business.
Net sales $936M, down 4.9% (down 6.7% constant currency); GAAP net loss ($45M) or ($0.22) per share.
Dentsply Sirona appoints Daniel Scavilla as CEO; preliminary Q2 sales ~$935M and adj. EPS $0.50-0.52
Daniel Scavilla appointed President & CEO effective Aug 1, 2025, succeeding Simon Campion who departs July 31, 2025.
Dentsply Sirona issues $550M of 8.375% junior subordinated notes due 2055, repays $435M bridge loan
Issued $550M aggregate principal of 8.375% Fixed-to-Fixed Reset Rate Junior Subordinated Notes due September 12, 2055.
Dentsply Sirona prices $550M 8.375% junior subordinated notes due 2055
$550M aggregate principal amount of 8.375% fixed-to-fixed reset rate junior subordinated notes due 2055.
Dentsply Sirona appoints Matthew Garth as CFO, effective May 30, 2025
Matthew Garth named EVP & CFO; previously CFO & CAO of Scotts Miracle-Gro.
Dentsply Sirona Q1 net sales -7.7%; CFO Cueto departs, CEO Campion as interim PFO
Net sales $879M (-7.7% YoY); organic sales -4.4% including -4.0% Byte impact.
Dentsply Sirona enters $435M bridge loan agreement, borrows full amount to repay commercial paper
Bridge loan facility of $435M, 364-day maturity, borrowed in full at closing on March 19, 2025.
Dentsply Sirona Reports FY 2024 Net Sales of $3,793M, Net Loss of $910M, and Provides 2025 Outlook
FY24 net sales decreased 4.3% to $3,793M; organic sales down 3.5% including a 1.2% Byte sales impact.
Dentsply Sirona starts strategic review for Wellspect Healthcare unit
Wellspect provides bladder/bowel care products (LoFric, Navina); $2B TAM.
Dentsply Sirona discontinues at-home Byte aligner kits, expects Q4 refunds and asset write-offs
Byte at-home aligner systems and impression kits discontinued; focus shifts to in-person dentist oversight.
German criminal probe into Dentsply Sirona's 2016-2017 loans; interim CFO named
German authorities searched Company sites in Bensheim and Hanau on Nov 7, 2024 as part of criminal investigation into post-merger intercompany loans.
Dentsply Sirona Q3 GAAP loss of $494M, cuts FY24 outlook; CFO transition
GAAP net loss $494M ($2.46/sh) vs $266M loss a year ago; includes $495M goodwill impairment.
Dentsply Sirona suspends Byte aligner sales after FDA consult; Q3 rev ~$951M, impairment up to $550M
Voluntarily suspends sale/marketing of Byte aligners and impression kits in consultation with FDA.
Dentsply Sirona CFO Glenn Coleman resigns effective Nov 7, 2024; search underway
Glenn Coleman resigned as EVP, CFO effective Nov 7, 2024, to join another public company.
Dentsply Sirona Q2 net loss $4M, lowers FY24 outlook, begins restructuring
Net sales $984M (-4.2% YoY), organic sales -2.3%; GAAP net loss $4M ($0.02/share), adjusted EPS $0.49 vs $0.51.
Dentsply Sirona Q1 net sales $953M (-2.6%); adj. EPS $0.42, up 7.9% YoY
Net sales of $953M declined 2.6% YoY; organic sales down 1.9%.
Dentsply Sirona Q4 adj EPS $0.44, FY23 adj EPS $1.83; FY24 outlook adj EPS $2.00-$2.10
FY23 net sales $3,965M (+1.1% YoY), organic +2.2%; GAAP net loss $132M ($0.62/share).
Dentsply Sirona expects FY2023 sales at or above $3.94B, reaffirms adj. EPS $1.80-$1.85
Preliminary 2023 net sales expected at or above high end of prior $3.90-$3.94B range.
Dentsply Sirona sets 2026 adjusted EPS target of $3.00; authorizes $1B buyback
Company targets adjusted EPS of $3.00 in 2026 as part of three-year financial plan.
Dentsply Sirona Q3 net loss $266M; lowers FY23 guidance; appoints Brian Gladden to board
Q3 net sales flat at $947M, organic sales -0.3%; GAAP net loss $266M ($1.25/share) including $302M impairment.
Dentsply Sirona Q2 organic sales +2.3%, raises FY guidance; discloses material weakness
Q2 net sales $1,028M (+0.5% reported, +2.3% organic); GAAP EPS $0.40, adj. EPS $0.51.
On June 1, 2026, the Board of Directors (the “Board”) of DENTSPLY SIRONA Inc. (the “Company”) appointed John C. Fortson as the Company’s Executive Vice President & Chief Financial Officer, effective as of July 20, 2026 (the “Effective Date”).
On May 27, 2025, the Board of Directors (the “Board”) of DENTSPLY SIRONA Inc. (the “Company”) appointed Matthew E. Garth as the Company’s Executive Vice President & Chief Financial Officer, effective as of May 30, 2025 (the “Effective Date”).
the Board appointed Messrs. Michael J. Barber and Daniel T. Scavilla to the Board, effective immediately.
the Board appointed Messrs. Michael J. Barber and Daniel T. Scavilla to the Board, effective immediately.
Dr. Dorothea Wenzel notified the Board of her resignation as a member of the Board, effective immediately.
Additionally, on November 6, 2024, the Company appointed Simon D. Campion, the Company’s President and Chief Executive Officer and a member of the Company’s Board of Directors, to the additional role of interim principal financial officer
the date upon which Glenn G. Coleman will resign as the Company’s Executive Vice President, Chief Financial Officer, principal financial officer, and interim principal accounting officer, as has been previously disclosed.
On November 6, 2024, the Company appointed Kevin J. Czerney, currently the Company’s Vice President, Chief Audit Executive, to the role of Vice President & Chief Accounting Officer
On August 15, 2024, Glenn G. Coleman informed DENTSPLY SIRONA Inc. (the “Company”) of his decision to resign as Executive Vice President, Chief Financial Officer and principal accounting officer of the Company effective November 7, 2024, to pursue another opportunity.
On July 31, 2024, as part of the restructuring plan described in Item 2.05 herein, the Company eliminated the position of Executive Vice President, Chief Business Officer which is currently held by Mr. Andreas G. Frank, effective October 1, 2024, or such other date as mutually agreed to between the parties (the “Termination Date”).
Additionally, on July 25, 2024, Richard M. Wagner informed the Company of his decision to resign as Vice President, Chief Accounting Officer of the Company effective August 16, 2024, to pursue another opportunity.
In connection with Mr. Wagner’s resignation, Glenn G. Coleman, Executive Vice President, Chief Financial Officer, will assume the responsibilities of principal accounting officer on an interim basis, effective August 16, 2024.
Max materiality 0.90 · Median 0.62 · Most common event earnings